MNKD - רווח נקי למניה (EPS TTM) MannKind Corp

Steady demand for inhalation therapy and partnership royalties ensure a confident capital inflow for MannKind Corporation (MNKD). Local production in the US mitigates geopolitical risks, although the import of Asian components remains vulnerable. Efficient pharmaceutical logistics guarantee the integrity of medications during delivery. The change in per-unit profit over the last 12 months demonstrates current dynamics, where the current value is -0.24.
MNKD (MannKind Corp.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The resilience of MannKind Corporation (MNKD) is based on the patent protection of its technologies, despite a significant dependence on external distributors. Analyzing the company's EPS TTM dynamics on GURU.Markets, an investor can see the net profit allocated per share over a year, which allows for an assessment of the business's real yield after all expenses. This indicator serves as the basis for determining the asset's fair value amid capital volatility.